ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
advertisementadvertisement
NeuroToxicology
Volume 23, Issue 3, September 2002, Pages 375-384
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (214 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/S0161-813X(02)00078-5    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2002 Elsevier Science Inc. All rights reserved.

Effects of Perinatal Exposure to a Polybrominated Diphenyl Ether (PBDE 99) on Mouse Neurobehavioural Development

Igor BranchiCorresponding Author Contact Information, E-mail The Corresponding Author, 1, 2, Enrico Alleva2 and Lucio G. Costa1, 3

1 Department of Pharmacology of Natural Substances and General Physiology, University of Rome “La Sapienza”, Rome, Italy 2 Laboratorio di Fisiopatologia, Section of Behavioural Pathophysiology, Istituto Superiore di Sanità, Rome, Italy 3 Department of Environmental Health, University of Washington, Seattle, WA, USA

Received 15 February 2002; 
accepted 4 June 2002. 
Available online 17 September 2002.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Polybrominated diphenyl ethers (PBDEs), a class of widely used flame retardants, are extensively diffused in the environment as shown by several studies on sentinel animal species, as well as humans. Of particular concern are the reported high levels of PBDEs in human milk, as almost no information is available on their potential effects on developing organisms. We investigated the effects of perinatal PBDE exposure on mouse neurobehavioural development. 2,2′,4,4′,5-pentabromodiphenylether (PBDE 99; 0.6, 6 and 30 mg/kg per day) was administered daily to CD-1 Swiss females by gavage from gestational day (GD) 6 to postnatal day (PND) 21. Aroclor 1254 (A1254; 6 mg/kg per day), a PCB mixture, was administered following the same schedule and served as a positive control. The PBDE 99 medium dose had an effect on litter viability. Sensori-motor development analysis (PNDs 2–20) revealed a delayed appearance of climbing response in the PBDE 99 high-dose group. On PND 11, the homing test revealed a trend for treated animals, particularly the A1254 group, to be more active than controls. This activity level alteration was strongly increased on PNDs 34 and 60 in an open-field arena. On PND 60, treated mice showed also an altered thigmotaxis, spending more time in the centre of the arena than controls. At adulthood, A1254 treated mice were still hyperactive, whereas the PBDE 99 groups tended to be hypoactive. These findings showed that perinatal exposure to PBDE 99 produces several behavioural alterations and that its effects are not always similar to those of A1254. The possibility of exposure of neonates to PBDEs warrants further studies to characterise their developmental neurotoxicity.

Author Keywords: PBDE 99; Aroclor 1254; Neurobehavioural development; Mice; Perinatal exposure; Brominated flame retardants

Article Outline

1. INTRODUCTION
2. MATERIALS AND METHODS
2.1. Animals
2.2. Perinatal Treatment
2.3. Assessment of Effects on Pregnancy
2.4. Assessment of Somatic and Neurobehavioural Development (PNDs 2–20)
2.5. Ultrasonic Vocalisations (PNDs 4, 8 and 12)
2.6. Homing Test (PND 11)
2.7. Open-Field Test (PNDs 22, 34, 60 and 120)
2.8. Statistical Analysis
3. RESULTS
3.1. Effects on Pregnancy
3.2. Somatic and Neurobehavioural Development
3.3. Ultrasonic Vocalisations
3.4. Homing Test
3.5. Open-Field Test
4. DISCUSSION
Acknowledgements
References







NeuroToxicology
Volume 23, Issue 3, September 2002, Pages 375-384
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.